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A B S T R A C T
Purpose: This study investigates the performance of a cardiac-based seizure detection algorithm (CBSDA)
that automatically triggers VNS (NCT01325623).
Methods: Thirty-one patients with drug resistant epilepsy were evaluated in an epilepsy monitoring unit
(EMU) to assess algorithm performance and near-term clinical beneﬁt. Long-term efﬁcacy and safety
were evaluated with combined open and closed-loop VNS.
Results: Sixty-six seizures (n = 16 patients) were available from the EMU for analysis. In 37 seizures
(n = 14 patients) a 20% heart rate increase was found and 11 (n = 5 patients) were associated with ictal
tachycardia (iTC, 55% or 35 bpm heart rate increase, minimum of 100 bpm). Multiple CBSDA settings
achieved a sensitivity of 80%. False positives ranged from 0.5 to 7.2/h. 27/66 seizures were stimulated
within 2 min of seizure onset. In 10/17 of these seizures, where triggered VNS overlapped with ongoing
seizure activity, seizure activity stopped during stimulation. Physician-scored seizure severity (NHS3-scale)
showed signiﬁcant improvement for complex partial seizures (CPS) at EMU discharge and through 12 months
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P. Boon et al. / Seizure 32 (2015) 52–61 53(p < 0.05). Patient-scored seizure severity (total SSQ score) showed signiﬁcant improvement at 3 and
6 months. Quality of life (total QOLIE-31-P score) showed signiﬁcant improvement at 12 months. The
responder rate (50% reduction in seizure frequency) at 12 months was 29.6% (n = 8/27). Safety proﬁles were
comparable to prior VNS trials.
Conclusions: The investigated CBSDA has a high sensitivity and an acceptable speciﬁcity for triggering
VNS. Despite the moderate effects on seizure frequency, combined open- and closed-loop VNS may
provide valuable improvements in seizure severity and QOL in refractory epilepsy patients.
 2015 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vagus nerve stimulation (VNS) (VNS Therapy1, Cyberonics,
Houston, Texas, USA) is a safe and efﬁcacious treatment for
refractory epilepsy [1,2]. Currently VNS is delivered in an open-
loop fashion with continuous but intermittent (‘ON’ and ‘OFF’
cycles) stimulation of the vagus nerve. A hand-held magnet allows
on-demand stimulation to interrupt seizure activity [3]. Automated
seizure detection that triggers VNS could offer a solution for
patients unable to use the magnet due to clinical seizure
symptoms, a physical limitation, cognitive impairment, or for
nocturnal seizures. EEG and ECG studies have shown that ictal
heart rate increases occur in an average of 82% of epilepsy patients
[4].
This clinical trial investigates, for the ﬁrst time in an epilepsy
monitoring unit (EMU) setting, the performance of a novel cardiac-
based seizure detection algorithm (CBSDA) incorporated in a
neurostimulation device (AspireSR1, Cyberonics, Houston, Texas,
USA). In addition to standard open-loop VNS, this device provides
an automatic stimulation feature which is triggered in response to
ictal heart rate increases of at least 20% to deliver VNS in a closed-
loop fashion. The automatic stimulation feature delivers the same
stimulation waveform as open-loop VNS, although output current,
stimulation duration, and pulse width can be set independently.
Both open and closed-loop modes can be delivered in combination.
2. Methods
2.1. Study overview
The E-36 study was a prospective, multi-center study in VNS
candidates with a history of ictal tachycardia (iTC, 55% or 35 bpm
increase in heart rate, to a minimum level of 100 bpm). The
primary aim of the study was to demonstrate a seizure detection
sensitivity of at least 80% for iTC seizures by at least one detection
threshold setting, and to investigate the associated false positive
(FP) rate. Secondary outcome measures were latency to seizure
detection and effects on seizure duration, severity, frequency and
quality of life (QOL) over a 12-month treatment period. Patients
were implanted [5] with the new VNS device between April
2011 and June 2013 at 13 European sites (Fig. 2A, see Section 3).
Continuous video-EEG and ECG monitoring was performed during
3–5 days when the device was programmed with the closed-loop
VNS feature only. The new VNS device monitors the electrical
activity of the heart using the generator case and one VNS lead
electrode (Fig. 1). When a patient’s relative heart rate increases
above a programmed threshold for at least 1 s, a single VNS train
(preprogrammed to 30 or 60 s duration) is automatically delivered.
Six seizure detection algorithm (SDA) thresholds are available to
match individual patient ictal heart rate changes. In the trial,
patients were randomized to three different SDA settings (20%,
40%, 60% above baseline heart rate) during the EMU stay.
During the EMU, open-loop stimulation was disabled to allow
assessment of the automatic stimulation feature. Recordedseizures at the EMU were annotated by the clinical investigators.
Patients performed a 3-min step test to elicit non-ictal increases in
heart rate. The exercise test was not long enough to extrapolate FP
rate per hour, but was reviewed to determine the proportion of
sessions in which automatic stimulation was triggered. During
long-term follow-up, both open- and closed-loop VNS was active
using the SDA threshold deemed most appropriate by the
physician. Throughout the course of the study medication changes
were avoided unless considered medically necessary. Based on
records of concomitant medications, no signiﬁcant medication
changes occurred from baseline through long term follow-up. The
study was approved by the Competent Authorities and Ethics
Committees (EC). All patients signed informed consent. This study
is registered with ClinicalTrials.gov (NCT01325623).
2.2. Assessment of device performance
Sensitivity, potential FP rate, and latency were analyzed in two
ways: observed and modeled. The observed analysis reﬂects the
real world behavior of the device. As patients were randomized to
a speciﬁc SDA setting during EMU stay, the detection of each
seizure, based on associated cardiac changes, could only be
evaluated at the single SDA threshold to which the patient was
randomized. For the observed analysis, timestamps from detec-
tion logs that were downloaded from the implanted generator
were compared to the seizure annotations from the physicians
based on EEG. Not all EMU seizures could be included in the
observed analysis. To be included, the clinical study site needed to
download the detection log from the generator (a daily protocol
requirement), the SDA threshold had to be set to the randomized
setting dictated by the protocol, and the seizure needed to occur
while closed-loop stimulation was activated in isolation of other
VNS modes (Normal Mode or Magnet Mode). For the modeled
analysis, surface ECG recordings from the EMU stay were post-
processed through the seizure detection algorithm to simulate
outcomes at all possible device threshold settings ranging from
20 to 70%. ECG was collected as a referential montage with one
electrode placed over the lead incision site and one electrode place
over the generator implant location. Compared to the observed
analysis, more seizures could be included in the modeled analysis,
since the only requirement was that surface ECG was available
during the time of the seizure.
2.3. Calculation criteria and formulas
Sensitivity was calculated as the number of seizures detected,
divided by the number of physician-annotated seizures. A
detection window of 2 min around the annotated seizure onset
was established to identify true positives, according to a method
previously used in validation of an EEG-based seizure detection
software [6]. The observed analysis reports sensitivity based on
generator detection logs and the protocol-dictated, randomized,
device threshold setting (see Table 2). In the modeled analysis
sensitivity is reported by the magnitude of ictal heart rate increase
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Fig. 1. CBSDA description and demonstration of algorithm behavior. Complex partial seizure, SDA 20% threshold. In the AspireSR device, heart beats are recorded by
monitoring the electrical activity of the heart using the generator case and one VNS lead electrode. The device ﬁrmware ampliﬁes and ﬁlters these signals, identiﬁes the R-
waves, and calculates R–R intervals based on the detected beats. These R–R intervals are then processed through the CBSDA, which compares the most recent heart rate data
to a background rate established over approximately the previous 5 min of R–R intervals. The threshold above baseline heart rate required for seizure detection can be set in
10% increments (range: 20–70%) according to patient needs. Device performance is shown for a 26 year old female subject experiencing a bilateral temporal lobe complex
partial seizure. The upper panel shows the instantaneous heart rate based on surface ECG (gray), and the algorithm calculated foreground (black) and background (black
dashed) heart rates, as well as seizure start and stop times. The middle panel shows the relative heart rate, the key patient metric monitored by the device, as well as the SDA
threshold required for stimulation. The lower panel shows the R–R interval quality checks which are performed by the device algorithm that are intended to prevent muscle
noise from inﬂuencing the foreground and background heart rates; on this plot a value of 4 indicates the beat passed all quality checks and was included in the determination
of the relative heart rate; lower values (1 to 3) indicate the beat failed at least one constraint and was excluded from algorithm processing. The lower panel also shows
stimulations based on observed (solid gray bar) and modeled detections (dashed gray bar). This seizure was stimulated by AspireSR and ended during the period of
stimulation.
P. Boon et al. / Seizure 32 (2015) 52–6154(see Table 1), since the modeled analysis allows evaluation of all
seizures at all possible device threshold settings.
Latency was calculated as the time between annotated seizure
onset, deﬁned as a typical change in behavior or EEG whichever
came ﬁrst, and device detection for each true positive detection.
The latency is therefore bounded to 120 s, either positive orTable 1
Modeled sensitivity and potential false positive rate, based on post-processed ECG.
SDA threshold (%) Sensitivity for
iTC seizuresa
n = 15 (%)
Sensitivity as a function of percent hear
70%
n = 5 (%)
60%
n = 7 (%)
50%
n = 11 (%)
70 60 100 
60 60 100 85.7 
50 80 100 85.7 81.8 
40 93.3 100 85.7 90.9 
30 100 100 100 100 
20 100 100 100 100 
For each magnitude of heart rate increase category, the least sensitive SDA threshold c
threshold expected for seizure detection are shaded gray.
a iTC is deﬁned as ictal heart rate >100 bpm, and at least 55% increase, or 35 bpm in
b Potential false positive rate per hour utilized 2709.5 h of monitoring time at each 
c 95% conﬁdence interval (CI) calculated using 3000 bootstrap samples.negative, the latter indicating that detection preceded seizure
onset.
Each detection that occurred outside the 2-min window was
counted as a potential FP, and the average rate was calculated for each
SDA threshold setting as the total number of potential FP detections
divided by the total monitoring time.t rate increase from baseline Potential false positive rateb
(95% CI)c
(stimulations/h)
40%
n = 19 (%)
30%
n = 33 (%)
20%
n = 45 (%)
0.4 (0.30, 0.64)
0.6 (0.47, 0.89)
1.0 (0.78, 1.39)
89.5 1.8 (1.44, 2.35)
100 90.9 3.5 (2.83, 4.37)
100 97.0 97.8 6.9 (5.74, 8.25)
apable of detecting the category is shown in bold. SDA settings that are below the
crease, from baseline.
SDA setting.
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National Hospital Seizure Severity Scale (NHS3) [7] and the Seizure
Severity Questionnaire (SSQ) [8]. The NHS3 is a physician-scored
severity scale (1–27 range; 27 most severe). The Wilcoxon signed-
rank test was used to assess statistical signiﬁcance of changes in
seizure severity versus the baseline NHS3 score. The SSQ is
completed by patients and caregivers (1–7 range; 7 most severe).
Changes in severity versus baseline SSQ score were compared to
the minimally important change (MIC) threshold to determine
clinical signiﬁcance [9].
Baseline seizure frequency was reported as the total number of
seizures during 3 months prior to enrolment screening. Post-
baseline seizure frequency was obtained from seizure diaries
reported at each follow-up visit (3, 6, and 12 months post-
implant). The responder rate was deﬁned as the proportion of
patients with a 50% decrease in seizure frequency versus
baseline.
QOL data was collected at baseline using the QOLIE-31-P and
compared to data collected at post-baseline visits. Changes in QOL
from baseline were compared to the minimally important change
(MIC) threshold to determine clinical signiﬁcance [10].
Adverse events were collected and incidence rates tabulated
utilizing MedDRA dictionary version 17.0.
3. Results
Thirty-one of 35 enrolled patients were implanted with the
AspireSR device that includes a cardiac-based seizure detection
feature (Fig. 2B). Study procedures are summarized by Fig. 2A. Data
from 29 patients are available through 12 months of follow-up
(Fig. 2B). Patient demographics, including seizure types recorded
in the EMU, are found in Fig. 2C.
3.1. CBSDA performance
At the EMU, 87 seizures were annotated by the investigators.
Observed analysis for seizure detection was possible in 66/87
seizures from 16 patients in whom all protocol procedures were
followed, including: device detection logs were downloaded, SDA
threshold was set to the randomized setting dictated by the
protocol, and the seizure occurred while closed-loop stimulation
was activated in isolation of other modes (see Section 2). The ictal
heart rate change in these 66 seizures ranged from 14.5% to 100%
(decrease n = 6, increase n = 60). In 37/66 seizures (n = 14 patients)
a 20% increase in heart rate was found, surpassing the lowest
detection threshold of the device. 11/37 seizures (n = 5 patients)
were associated with iTC according to the strict study criteria of
55% or 35 bpm increase in heart rate to a minimum level of
100 bpm. For 11 iTC seizures that occurred in the EMU, observed
sensitivities ranged from 75% (SDA = 40%) to 100% (SDA = 20% and
60%; see Table 2). 2/8 iTC seizures that occurred in a patient with
SDA = 40%, were not detected. In one case the elevated heart
rate was not maintained for more than 1 s (a device design
requirement). In the other case, muscle artifact was believed to be
the reason for the missed detection.
In 27/66 annotated seizures, the ictal heart rate change
surpassed the SDA threshold and VNS was triggered. As latency
cannot be calculated in the absence of seizure detection, these
27 true positives only are summarized in the observed (based on
device detection logs) latency analysis. In the remaining 39/66
seizures where VNS was not triggered, 23/39 seizures were
associated with an ictal heart rate change of <20%, 14/39 had a
heart rate change less than the randomized SDA threshold, and the
remaining 2/39 had high ECG noise or did not cross the threshold
for >1 s (these two cases were described above).Compared to the observed analysis, more seizures could be
included in the modeled analysis, since the only requirement was
that surface ECG was available during the time of the seizure (see
Section 2). Concurrent ECG and EEG recordings, allowing modeled
analysis for seizure detection, were available in 86/87 annotated
seizures from 18 patients. In 45/86 (n = 15 patients) a 20%
increase in heart rate was found. 15/45 seizures (n = 6 patients)
were associated with iTC. Table 1 reports the modeled sensitivity at
every available device SDA setting for all seizures with heart rate
changes 20% (n = 45), the types of seizures for which the
detection algorithm was designed. Results are presented by
magnitude of ictal heart rate increase. The least sensitive SDA
threshold capable of detecting seizures with a particular heart rate
change is shown in bold (below threshold categories are shaded
gray).
Both the observed and modeled sensitivity analyses demon-
strate that at least one SDA setting had a 80% sensitivity, meeting
the primary study endpoint. Ictal heart rate change as observed in
this study was highly variable. Of the 18 patients in whom seizures
were annotated during the EMU, 13 had more than one seizure.
Among patients with multiple seizures, the mean standard
deviation (SD) of change in ictal heart rate was 16% (maximum
SD 33%, minimum SD 7%).
The mean observed (based on device detection logs) potential
FP rate ranged from 0.5 to 7.2 per hour, depending on the SDA
setting (Table 2). Consistent with the observed clinical results, the
modeled analysis indicated a potential FP rate of approximately
0.4–6.9 per hour, depending on the SDA sensitivity setting
(Table 1). During the EMU, 28 patients completed 127 exercise
sessions which consisted of at least 3 min of stair step exercise. In
55.9% (71/127) of the sessions VNS was not triggered, in 20.5% (26/
127) of the sessions one triggered stimulation occurred, and in
23.6% (30/127) of the sessions VNS was triggered twice during the
3 min step exercise. After EMU discharge, patients underwent both
open- and closed-loop VNS. The mean overall duty cycle exceeded
the Normal Mode setting by <3% at the 3, 6, and 12 month follow-
up periods pointing to modest FP rates in the ambulatory setting.
The effect on overall duty cycle can be alternately summarized as a
mean closed-loop stimulation rate of <2.1/h at each follow-up
period. This indicates that normal daily activity such as physical
exercise did not compromise performance, and the device safety
features limit the addition of automatic stimulation to the Normal
Mode duty cycle. It should be noted that physicians most typically
selected mid-range detection thresholds during the ambulatory
phase; together the 40% and 50% detection thresholds accounted
for over 60% of patients at the 12 month follow-up.
3.2. Latency
The observed latency could be calculated for each true positive
detection, i.e. those stimulated within 2 min of seizure onset. This
included 27 seizures from the total of 66 investigator annotated
seizures in the observed analysis. The median observed latency
ranged from 6 (SDA = 20%) to 35 s (SDA = 60%) after seizure onset
(Table 2). For iTC seizures (n = 11 seizures), the median observed
latency ranged from 14.5 s before seizure onset (SDA = 20%) to 27.5 s
(SDA = 40%) after seizure onset. Similar results were collected for
modeled data (not shown). Generally, increasing the sensitivity of the
SDA threshold resulted in earlier seizure detections.
3.3. Effect of closed-loop VNS on seizure duration and severity during
the EMU
In total, 27/66 EMU seizures from the observed analysis were
stimulated within 2 min of seizure onset. In 17 seizures, the
triggered VNS overlapped with ongoing seizure activity, and seizure
(A)
(B)
(C)
Fig. 2. Study protocol overview. Panel A: Seizure diary, SSQ, NHS3, and QOLIE-31-P were collected at baseline. Two weeks following implant surgery, standard open-loop VNS
was initiated and titrated for up to 2 weeks. This period allowed patients to acclimate to VNS stimulation, but restricted output to a subtherapeutic level to facilitate seizure
recording during a 3–5 day EMU stay (2–4 weeks after implant). As part of EMU procedure the subject received Normal Mode stimulation for 1 h (to increase output to
therapeutic levels), Normal Mode plus Automatic stimulation for 2 h (to introduce new feature), and then automatic stimulation only until EMU discharge. The SDA threshold
randomization was performed on day 1 of EMU. At EMU discharge, both open- and closed-loop VNS were activated and the SDA threshold was programmed by the physician
to the most suitable setting. Follow-up visits occurred at 3, 6, and 12 months. The study will continue to follow patients through 2 years after implant. Panel B shows the status
of patients enrolled in the trial. Four screen failures occurred: low seizure rate during baseline (1), underlying cardiac conditions (2), and withdrawn patient consent (1). The
ﬁrst subject was implanted with a ﬁrst version of the new generator; the remaining 30 subjects were implanted with version 2, which included modiﬁed gain and ﬁlter
settings for heart beat sensing. The population used for safety analyses consists of all subjects who provided consent and were implanted with either generator version
(n = 31 subjects). The population used for performance analyses consists of all subjects who were implanted with version 2 and underwent an EMU stay (n = 30 subjects). One
patient discontinued the trial prior to the 12 month follow-up visit due to an adverse event (AE) of diarrhea and vomiting. The patient recovered from the AE, but VNS was
permanently programmed ‘OFF’. Panel C describes patient characteristics.
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Table 2
Observed sensitivity, potential false positive rate, and latency, based on device detection logs.
SDA threshold (%) Sensitivity for
iTCa seizures
(n = 11)
Sensitivity for seizures with
20% heart rate change
(n = 37)
Sensitivity for all observed
analysis seizures (n = 66)
False positive rate per hourb
(95% CI)c
(stimulations/h)
Median latencyd
(min, max)
(s)
60 1/1 (100%) 3/11 (27.3%) 3/16 (18.8%) 0.49 (0.20, 0.96) 35.0 (4, 40)
40 6/8 (75%) 7/15 (46.7%) 8/23 (34.8%) 2.72 (1.70, 3.91) 27.5 (0, 57)
20 2/2 (100%) 11/11 (100%) 16/27 (59.3) 7.15 (5.31, 9.94) 6.0 (112, 105)
a iTC is deﬁned as ictal heart rate >100 bpm, and at least 55% increase, or 35 bpm increase, from baseline.
b Potential false positive rate per hour utilized 609.6, 953.9, and 759.3 h of monitoring time for SDA thresholds 20%, 40%, and 60%, respectively.
c 95% conﬁdence interval (CI) calculated using 3000 bootstrap samples.
d Results from 27 true positive seizure detections among the 66 seizures available for the observed analysis.
P. Boon et al. / Seizure 32 (2015) 52–61 57activity stopped during stimulation in 10/17 (58.8%) seizures,
including 4/4 (100%) simple partial, 6/11 (54.5%) complex partial,
and none of the secondarily generalized seizures (0/2). Fig. 3 (panels A
and B) shows an example of the impact of triggered VNS on the EEG
and displays the relationship between detection latency and seizure
duration (panel C). Seizures stimulated near annotated onset, were
shorter in duration (p < 0.01).
After 3–5 days of treatment with closed-loop VNS only, patients
experienced statistically signiﬁcant reduction in seizure severity
compared to baseline among CPS according to the NHS3 scale
(mean change 2.5 points; 19 subjects, p = 0.002).
3.4. Long-term changes in seizure severity, seizure frequency and QOL
Twenty-nine patients completed 12 months of follow-up
(96.7% compliance rate). Improvement in physician-rated seizure
severity (NHS3) at EMU discharge persisted during long-term
follow-up at the 3, 6, and 12 month assessments; mean NHS3
severity changes for patients with CPS were 1.6 (20 subjects;
p = 0.037), 2.5 (20 subjects; p = 0.004), and 2.3 points (20 sub-
jects; p = 0.002), respectively.(A)
Fig. 3. The impact of triggered VNS following an ictal heart rate increase detection. Panels 
bilateral temporal lobe complex partial seizure. The device was set to an SDA threshold 
stimulation, slowing of the focal synchronized sharp- and -slow wave activity is observ
resembling pre-ictal EEG patterns. Panel C shows the relationship between seizure de
(n = 10 in 5 patients), those stimulated near annotated onset, were shorter in durationAdditionally, several subscales of the SSQ (patient-rated)
exceeded the Minimally Important Change (MIC) criteria [9] for
clinical signiﬁcance at 12 months (Fig. 4).
The responder rate was 24.1% (n = 7/29) at 3 months, 20.0%
(n = 6/30) at 6 months, and 29.6% (n = 8/27) at 12 months. For
partial seizures it was 25.9% (n = 7/27) at 3 months, 25.0% (n = 7/
28) at 6 months, and 32.0% (n = 8/25) at 12 months. At 6 months
the median Normal Mode stimulation parameters were:
1.250 mA output current, 250 ms pulse width, 30 s ‘ON’/5 min
‘OFF’, 20 Hz signal frequency; automatic stimulation settings:
1.188 mA, 375 ms pulse width, and 60 s ‘ON’ time. Median
parameters were identical at 12 months, except automatic
stimulation pulse width decreased to 250 ms and the output
increased to 1.375 mA.
Improvement in QOL was found at the 12-month follow-up
visit. The following domains exceeded the Minimally Important
Change (MIC) criteria for clinical signiﬁcance [10]: emotional well
being (e.g. happiness, decreased anxiety or depression), social
function (e.g. visiting friends or relatives), cognitive function (e.g.
memory and concentration), seizure worry (e.g. decreased fear of
injury or embarrassment), and overall QOL.A (pre-ictal) and B (ictal) show data from a 26-year old female patient experiencing a
of 20% and stimulation was triggered 6 s after seizure onset. Following the onset of
ed, followed by an abrupt and generalized desynchronization of rhythmic activity
tection latency and seizure duration. For seizures that ended during stimulation
 (linear regression, p < 0.01).
(B)
Fig. 3. (Continued ).
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The new VNS device did not produce any unanticipated adverse
device effects and the surgical implantation was well tolerated.
Data were not collected on patients’ awareness of stimulation,
however the adverse event proﬁle indicates a similar tolerability
proﬁle to open-loop VNS. Dysphonia was reported in nine patients
(29.0%) and was the most common adverse event after VNS
activation. One patient discontinued the trial prior to the 12 month
follow-up visit (Fig. 2B).
4. Discussion
This study is the ﬁrst clinical trial in epilepsy to prospectively
evaluate the performance of a CBSDA incorporated into a closed-
loop VNS device. A high sensitivity for seizure detection was
reached when the appropriate detection threshold was applied,
and the FP rate was acceptable.Seizure detection algorithms have mainly been EEG-based
[11], which depending on the type of seizure, requires the
capability to detect a wide variety of speciﬁc EEG abnormalities.
Detection algorithms based on intracranial EEG recordings are
promising and currently applied for neurostimulation triggering,
but they remain limited to a carefully selected patient population
[12]. Heart rate changes associated with seizures have been
extensively investigated [4]. ECG is less complex and obtrusive to
record, and seizure-related ECG changes are more generic and
present in the majority of patients. Therefore, seizure detection
based on cardiac recordings would appear a promising alterna-
tive.
There have been few studies assessing real-time seizure
detection systems based on measures obtained from an ECG alone
[13–17] or in combination with EEG [18–20]. Most studies were
conducted in small samples of neonates [13,14,16,18] and
retrospectively analyzed pre-existing data. Seizure detection
sensitivity ranged from a low of 54.5% (corresponding speciﬁcity
(C)
Fig. 3. (Continued ).
P. Boon et al. / Seizure 32 (2015) 52–61 59of 77.3%) [14] to a high of 85.7% (corresponding speciﬁcity of
84.6%) [16]. In our study, when the patient exhibited large ictal
heart rate change and more selective SDA thresholds were used,
less than 1 false detection per hour occurred. We considered the
combination of sensitivity and FP rate to be clinically appropriate
for implementation in a neurostimulation device. Combined
recording of other physiological parameters – such as accelero-
metry leading to multimodal and individualized seizure detection
– may be required when the algorithm is to be used solely for
seizure alerting purposes or objective seizure counting in
therapeutic trials.0
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Fig. 4. Clinically signiﬁcant improvement in patient and caregiver scored seizure
severity (SSQ). The plot shows the mean change from baseline SSQ score
(dimensionless units) at 3, 6, and 12 months for each of 6 subscales and the
overall total score. Positive values indicate improved seizure severity compared to
baseline. All subscales and the total SSQ score improved from baseline, and those
exceeding the minimally important change (MIC) criteria represent clinically
signiﬁcant improvement in patient health. At 12 months, the full SSQ was
completed by 26/30 patients. Each of the categories exceeding MIC at 12 months
(activity, overall recovery, post-ictal physical and post-ictal cognitive recovery)
previously showed clinically signiﬁcant improvement at the 3 and 6 month follow-
up periods.Despite the fact that a priori iTC was an inclusion criterion for
the study, and that an extensive literature review [4] demonstrated
that approximately 82% of epilepsy patients have signiﬁcant ictal
heart rate increase, only approximately one-third of the prospec-
tively recorded E-36 seizures were associated with iTC. This
discrepancy reﬂects a signiﬁcant variability in ictal heart rate
changes in individual patients along with the fact that none of the
published studies were prospective studies.
The pulse generator design includes CBSDA thresholds as low as
20%, which supports the consideration that patients with ictal
heart rate increases less than the strictly deﬁned iTC could also be
considered for closed-loop VNS treatment.
The limitation of the randomization to speciﬁc detection
thresholds was overcome by performing a modeled analysis in
which recorded surface ECG data were reanalyzed post hoc by the
detection algorithm for all programmable thresholds ranging
from 20% to 70%. The higher the seizure-associated heart rate
increases are, the higher the SDA threshold can be programmed,
and the lower the FPs are expected to be. On the other hand,
seizures associated with heart rate increases of only 20% could be
detected with a high sensitivity at the price of 7 FPs per hour. In
comparison, a Normal Mode duty cycle of 10% used in isolation of
other modes would deliver a similar number of stimulations per
hour (approximately 11/h), without the potential beneﬁt of
temporal targeting of stimulation to seizure activity. Two design
features limit the extent to which the automatic stimulation
feature can increase the programmed Normal Mode duty cycle.
First, after delivery of an automatic stimulation burst the device
enforces an ‘OFF’ period, equal in duration to the selected
automatic stimulation ‘ON’ time, in which no further automatic
stimulation can occur. Secondly, automatic stimulation resche-
dules or delays the next Normal Mode stimulation, by resetting
the Normal Mode ‘OFF’ period. Taken together the impact of
automatic stimulation on the overall duty is modest, increasing
the mean Normal Mode setting by <3% during long term follow-
up.
During the trial, patients were not limited in physical activity
and exercise. On the contrary, they were instructed to perform
daily submaximal exercise activities to determine the likelihood of
triggering during moderate physical exertion. In more than half of
the exercise sessions automatic stimulation was not triggered,
since the dynamics of heart rate increase associated with seizure
activity (reﬂected by the rate of change) differs from physiological
heart rate increase during exercise and the algorithm is designed to
detect rapid relative heart rate changes. At 3, 6, and 12 month
follow-up periods, device logs of CBSDA stimulations revealed only
modest FP rates in the ambulatory setting. This implies that normal
daily activity such as physical exercise did not signiﬁcantly add to
the programmed open-loop duty cycle, and this outcome was
likely related to more suitable patient-speciﬁc CBSDA settings
during the long term follow-up compared to the randomized
assignments within the EMU.
In three different patients CPS stopped during triggered VNS.
The relatively short mean duration of these CPS [21] suggests a
shortening effect for acutely delivered VNS. These durations
however could not be compared with historical information
from the same patients due to limited availability of historical
patient records. Initial reports comparing seizures treated with and
without closed-loop VNS in an EMU setting are promising [22].
The design of this study did not allow for direct comparison to
patients treated with open-loop VNS alone. However, the impact
of automatic stimulation on seizure duration and seizure
severity in the EMU (when only closed-loop VNS was active)
suggests that acute delivery of VNS at seizure onset may be
beneﬁcial. Both seizure severity and QOL were signiﬁcantly
improved early in the trial by combined closed- and open-loop
P. Boon et al. / Seizure 32 (2015) 52–6160VNS during the long-term follow-up. Although the magnitude of
noted improvements may appear modest compared to the overall
range of these scales, many of these improvements were statistically
signiﬁcant or exceeded the minimally important change (MIC)
threshold for clinical signiﬁcance. In this study the responder rate of
30% was relatively low compared to other open VNS trials [23]. One
of the reasons could be the relatively low output current that
patients were ramped up to at 12 months follow-up due to the study
design. Longer follow-up data will have to demonstrate whether
responder rates increase which is to be expected from results in
long-term studies. Beneﬁcial effects of the closed-loop VNS modality
are primarily expected in the QOL and seizure severity assessments
as the algorithm has to detect heart rate change before it can trigger
stimulation, and this change occurred prior to clinical seizure onset
in only a minority of patients.
5. Conclusion
The present study prospectively demonstrated the ability to
detect seizures based on cardiac changes as low as a 20% above
baseline heart rate with high sensitivity. Limitations of this study
include the relatively small sample of seizures captured during the
EMU that were associated with iTC. Due to the apparent intra-
patient variability of seizure-associated heart rate increases,
identiﬁcation of candidates for this treatment in an outpatient
clinical setting may prove challenging. A practical approach would
be to select suitable patients during a presurgical EMU admission
during which at least one recorded seizure is found to be associated
with at least 20% heart rate increase.
Combined open- and closed-loop systems may have differential
and additive effects in patients with drug resistant epilepsy. Open-
loop treatment might provide neuromodulatory effects which take
time to establish, whereas acute treatment via the closed-loop
feature may more rapidly terminate or decrease duration and/or
severity of the ictal events. Despite the moderate effects on seizure
frequency, combined open- and closed-loop VNS may provide
valuable improvements in seizure severity and QOL in refractory
epilepsy patients. Our results demonstrate that ECG-based seizure
detection can provide a valuable addition to the currently available
treatment modalities.
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